Erlotinib in Women With Squamous Cell Carcinoma of the Vulvar
Status:
Completed
Trial end date:
2012-10-01
Target enrollment:
Participant gender:
Summary
In this research study we are looking to see how vulvar cancer responds to erlotinib therapy.
Two distinct patient populations are targeted: women with locally advanced measurable
squamous cell carcinoma of the vulva, primary or recurrent, who are candidates for definitive
treatment with surgery or chemoradiation (Cohort 1) and women with radiographically
measurable distant metastatic cancer either at time of presentation or with recurrence
(Cohort 2). Another goal of this study is to learn more about the proteins and genes present
in vulvar cancer and how they may affect response to erlotinib. Erlotinib treats cancer by
preventing cancer cells from growing and multiplying. It does this by blocking certain
proteins that are on the surface of some types of cancer cells. Laboratory tests show that
vulvar cancer cells have high levels of these proteins.
Phase:
Phase 2
Details
Lead Sponsor:
Dana-Farber Cancer Institute
Collaborators:
Beth Israel Deaconess Medical Center Brigham and Women's Hospital Genentech, Inc. Women and Infants Hospital of Rhode Island